Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $9.91 and last traded at $9.89, with a volume of 31150 shares. The stock had previously closed at $9.72.
Wall Street Analysts Forecast Growth
Separately, Citigroup upgraded shares of Fresenius SE & Co. KGaA to a "strong-buy" rating in a research note on Friday, October 25th.
Get Our Latest Stock Report on Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA Stock Down 2.1 %
The business's 50 day moving average is $9.21 and its 200-day moving average is $9.12. The company has a quick ratio of 1.05, a current ratio of 1.36 and a debt-to-equity ratio of 0.57.
Fresenius SE & Co. KGaA Company Profile
(
Get Free Report)
Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Further Reading
Before you consider Fresenius SE & Co. KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. KGaA wasn't on the list.
While Fresenius SE & Co. KGaA currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
